Search results

Filter

Filetype

Your search for "*" yielded 126749 hits

Kontakt

Personal Sök bland medarbetare på sidan Personal Ledning Ergonomi och aersolteknologi är en avdelning vid institutionen för Designvetenskaper. AvdelningsföreståndareAneta Wierzbickaaneta [dot] wierzbicka [at] design [dot] lth [dot] se (aneta[dot]wierzbicka[at]design[dot]lth[dot]se) Prefekt vid institutionenJessica Wadinjessica [dot] wadin [at] design [dot] lth [dot] se (jessica[dot]wadin[at]design

https://www.eat.lth.se/kontakt - 2025-12-13

Forskningspersoner sökes

Har du haft en stroke eller lever med en ryggmärgsskada och har begränsad rörlighet i överkropp/armar? Lunds universitet deltar med europeiska universitet och företag i ett forskningsprojekt om smarta tekniska hjälpmedel för människor med motorisk funktionsnedsättning i armar och händer. Nu söker vi forskningspersoner som kan bidra med kunskap om detta och vill hjälpa till med utformningen av fram

https://www.eat.lth.se/delta-i-forskningsstudie - 2025-12-13

Synergonomisk riskbedömning – VERAM

Varför är synergonomi viktigt?Den visuella miljön påverkar oss på flera sätt. Nästan hälften av oss är mer känsliga för visuella stimuli och får då i högre grad ögonbesvär, huvudvärk och belastningsbesvär. Det finns en direkt koppling mellan ögonbesvär och nack-/skulder besvär, om vi måste anstränga ögonen vid närarbete – ökar muskelaktiviteten i nacke, axlar och skuldror, vilket kan leda till smä

https://www.eat.lth.se/veram - 2025-12-13

Om oss

Vi undersöker hur människor och teknik fungerar tillsammans i olika miljöer och organisationer – och vad det betyder för utformningen av tekniska lösningar och sätt att arbeta. Vi arbetar för att förstå hur människor interagerar med och påverkas av sin omgivning. Denna omgivning omfattar allt från den fysiska miljön och relationer med andra människor till tekniska produkter och system. Vår forskni

https://www.eat.lth.se/om-oss - 2025-12-13

Certec

Forskargruppen Certec gick 2024 samman med Avdelningen för ergonomi och aerosolteknologi vid Designvetenskaper, LTH, Lunds universitet. Gruppens forskning handlar om människa, teknologi, pedagogik och design i ett samhälle för alla, och utgår från den berördas perspektiv och den livssituation personen befinner sig i. Att verka för ökad jämlikhet är ett av gruppens mål, och universell utformning är

https://www.eat.lth.se/certec - 2025-12-13

Start

CREATE Health: Translational Cancer Center CREATE Health develops and translates cutting-edge diagnostic and therapeutic innovations into real-world clinical solutions that measurably improve patient outcomes and advance public health. We combine state-of-the-art technologies, including AI-driven data analytics, next-generation sequencing, advanced molecular imaging, precision biologics and target

https://www.createhealth.lth.se/start - 2025-12-13

Organization

Centre Management Sara EkCenter Director, Director CanFastersara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se) Kristina LundbergDeputy Directorkristina [dot] lundberg [at] immun [dot] lth [dot] se (kristina[dot]lundberg[at]immun[dot]lth[dot]se) Corinna RichterResearch Coordinatorcorinna [dot] richter [at] immun [dot] lth [dot] se (corinna[dot]richter[at]immun[dot]lth

https://www.createhealth.lth.se/about/organization - 2025-12-13

Impact

Principle Investigators within CREATE Health have founded several spin-off companies which are already helping patients all around the world. Beside that, tens of research articles with ground-breaking discoveries have been published in renowned high-impact journals influencing and deepening the knowledge in the cancer field. Two EU co-funded CanFaster programs brought 32 international talents to

https://www.createhealth.lth.se/impact - 2025-12-13

Recruitment

Open positions will be advertised on Lund University's website and on our social media channels.If you are a student and interested in doing a Master's or ExJobb project, please contact the PI of the group of interest directly.

https://www.createhealth.lth.se/about/recruitment - 2025-12-13

Partners

Links will open on the respective websites.Region SkåneMedicon VillageCHUV in LausanneTMUCI in Tianjin, ChinaOslo Cancer ClusterWorking together is an integral part of CREATE Health’s DNA. We can proudly say that CREATE Health’s researchers are highly engaged in many different collaborations and networks – too many to name all of them here. For detailed information on our researchers’ collaborativ

https://www.createhealth.lth.se/about/partners - 2025-12-13

Spin-off companies

Lead BiologicsLead Biologics was founded in 2022 by Thoas Fioretos, Carl Sandén and Marcus Järås (Lund University), Kjell Sjöström (Innovagen) and Niklas Landberg (SUS). The company combines state-of-the-art technologies with unique patient cohorts to identify multiple novel therapeutic targets in leukemias and solid tumors. The aim is to develop a first-in-class treatment against SLAMF6. A majors

https://www.createhealth.lth.se/impact/spin-companies - 2025-12-13

CanFaster

The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility across borders" philosophy. The CanFaster programme has attracted international PhD and Postdoc fellows (ER) with an interest in applied medical research in oncology

https://www.createhealth.lth.se/canfaster - 2025-12-13

CanFaster Publications

The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.Authors: Meng, P., Dalal, H., Chen, Y., Brueffer, C., Gladchuk, S., Alcaide, M., ... &

https://www.createhealth.lth.se/impact/canfaster-publications - 2025-12-13

Inducing anti-tumor immunity with in-situ direct reprograming of cancer cells to cDC1s

Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient antigen presentation mediated by MHC downregulation and exclusion of functional antigen-presenting cells (APCs) from the tumor microenvironment (TME) are critical evas

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/inducing-anti-tumor-immunity-situ-direct-reprograming-cancer-cells-cdc1s - 2025-12-13

Next generation immuno-oncological targets for cancer therapy

Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/next-generation-immuno-oncological-targets-cancer-therapy - 2025-12-13

Subtype-dependent biomarkers for systemic therapy in bladder cancer

Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health outcomes [1].To patients with superficial cancer limited to the mucosa of the urinary bladder, the prognosis is good, but once the tumor has grown into the muscle-laye

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/subtype-dependent-biomarkers-systemic-therapy-bladder-cancer - 2025-12-13

About

CREATE Health, inaugurated in 2006 with a focus on precision medicine, is a strategic center for translational research focusing on the early diagnosis and prognosis of cancer, as well as the development of novel treatment strategies. Our approach is translational - It starts from a specific need, identified by our clinical partners. We use novel technological approaches to find the relevant solut

https://www.createhealth.lth.se/about - 2025-12-13

Research

Our research accompanies the entire patient journey, from initial diagnosis through treatment and companion diagnostics to quality-of-life enhancement during and after cancer. We deliver translational solutions that start from specific clinical needs identified by our clinical partners, leveraging novel technological approaches to accelerate implementation into the clinic with dramatically reduced

https://www.createhealth.lth.se/research - 2025-12-13